Business Wire

GALDERMA

Share
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio

Galderma will be presenting the latest data from the Sculptra® (injectable poly-L-lactic acid, PLLA-SCA) Cheek Wrinkle and Alluzience® (abobotulinumtoxinA solution) STAR studies at the 21st Aesthetic & Anti-Aging Medical World (AMWC) Congress, taking place in Monaco, from March 30 to April 1, 2023. Results demonstrate high aesthetic improvement as well as patient and investigator satisfaction for both products, reinforcing the strength of the company’s highly differentiated aesthetic portfolio, and underscoring its commitment to delivering science, innovation, and a premium experience throughout the treatment journey.1,2

Data from the innovative Sculptra Cheek Wrinkle study, a large clinical registration trial in the United States, show the long-lasting effectiveness of the treatment for cheek wrinkle correction over a two-year period.1 Sculptra is the first and original collagen stimulator with the unique PLLA-SCA3,4,5,6,7,8 that addresses the root causes of the skin aging process by stimulating the body’s own collagen production.9 This helps restore the skin’s foundation and structural function, gradually improving the its firmness, increasing skin elasticity and improving skin quality and radiance. Results are natural, progressive and proven to last over two years.10,11,12,13,14

In the study, the response rate at month 12 was significantly higher for Sculptra compared to the control group (71.6% vs 26.1%). At months seven to 12, those treated with Sculptra also had improved dynamic wrinkles, and even greater proportions had improved aesthetic appearance (≥93%), improved radiance, skin tightness, and jawline contour (≥86%). Patient satisfaction was high with ≥92% satisfied with their appearance and agreeing their skin’s natural glow was improved two years after treatment.1

In the 12-month extension study for the Sculptra treated arm, with no additional treatment, response rate remained high with aesthetic improvement rates of ≥94% at months 19-24, supporting maintained effects on wrinkles through two years. Results also demonstrated the safety profile of Sculptra. Sculptra was well tolerated with adverse events mostly mild and transient, and no new treatment-related adverse events reported in the 12-24 month follow-up.1

Galderma will also present the latest data from Alluzience’s first phase IV study, STAR, at AMWC. Approved in Europe in June 2021, Alluzience is Europe’s first ready-to-use (RTU) liquid neuromodulator for the treatment of moderate to severe glabellar lines (GLs - frown lines).

The clinical development program of Alluzience has shown rapid onset of effect, starting on day one, a long duration up to six months and improved psychological well-being after treatment.15 The objective of the STAR study was to assess subject and investigator experience using a RTU versus powder neurotoxin and aesthetic improvement, satisfaction and safety after just one treatment during a six-month follow-up period.2

At month one, almost all (99%) of those treated with Alluzience had aesthetic improvement in GLs at maximum frown, which persisted in ~76% up to month six. At month six, most subjects felt that they looked natural (95%) and refreshed (85%) and were satisfied with their appearance (88%). Results also showed high investigator satisfaction, 100% agreeing that it fulfilled their expectations, was easy to use and learn and required the fewest possible steps for its purpose. In 81% of treatment sessions, investigators preferred using the RTU formulation over powder. In addition, in 97% of treatment sessions, investigators felt that using a RTU solution such as Alluzience resulted in substantially less waste and that this was better for the environment.2

 

“The results from both of these important and unique studies reinforce
not only the strength of our broad aesthetic portfolio – for both patients
and physicians – but also our commitment to exploring innovative
approaches to deliver cutting-edge science as effective treatments.
We’re excited to share these data and more at the AMWC congress
and exchanging with the scientific community”

 

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF RESEARCH & DEVELOPMENT
GALDERMA

 

New techniques and approaches for the heavy face and the latest data from across the portfolio to be showcased at the congress

As a leader in bringing cutting-edge products to market and in providing the scientific community with individualized treatment approaches, training and business support, Galderma’s extensive presence at AMWC demonstrates its ongoing dedication to advancing dermatology for every skin story.

The focus of the Galderma symposium, titled Aesthetic Lives: Lifting the heavy face will explore the aesthetic journey as a long-term endeavor, using Galderma Holistic Individualized Treatments™ (HIT) to discover the aesthetic lives of patients and the medical professionals who treat them as we shape the future of aesthetics. The event will take place on Thursday, March 30 at 2:00 PM in the Prince Pierre Auditorium.

About Sculptra®

SCULPTRA is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin’s structural foundation, providing long-term results for more than two years.3-13 SCULPTRA was first approved in 1999 in Europe, and it is currently available in more than 40 countries globally.

SCULPTRA works to stimulate the skin’s own collagen production9 to provide firm and radiant skin. It is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, and scars, and for signs of skin aging.16

About Alluzience®
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.17 It should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.17 Dosing and treatment intervals depend on assessment of the individual patient’s response.17 The treatment interval should be no more frequent than every three months.17 For more information, please see the Summary of Product Characteristics.17

Alluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in several European countries.

About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience and Sculptra in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Aklief®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin® in Dermo-cosmetics. For more information, visit www.galderma.com.

References:

1 Fabi S. Poster presented at AMWC 2023.
2 Chadha P. Poster presented at AMWC 2023.
3 FDA. Summary of safety and effectiveness data. 2023
4 Data on file. MA- 54151
5 Asius J et al. Inventors. US patent US 7,731,758 B2,2021
6 Data on file. MA-53568
7 Mest DR, et al. Dermatol Surg. 2006
8 Bohnert K et al. Plast Reconstr Surg. 2019
9 Hexsel D, Dermatol Surg. Letters and Communications. 2020
10 Baron J. Abstract presented at IMCAS 2023. (MA-54104)
11 Goldberg D et al. Dermatol Surg. 2013
12 Narins RS, et al. J Am Acad Dermatol. 2010
13 Brandt FS, et al. Aesthet Surg J. 2011
14 Data on file. MA-48331
15 Hilton et al. Dermatol Surg 2022;48:1198-202
16 Sculptra IFU. 2018.
17 Alluzience Summary of Product Characteristics, 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005096/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tigo Energy Drive Towards Total Quality Solar Pays off With 1,000-System Green Glove Milestone5.2.2025 15:00:00 CET | Press release

Tigo Green Glove milestone covers installations on four continents, delivering comprehensive support to Commercial & Industrial (C&I) customers, and is expanding for residential installers. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” “Company”), a leading provider of intelligent solar and energy software solutions, today announced solar installers across four continents have enrolled more than 1,000 systems in the Tigo Green Glove program. Designed by Tigo as one of the main pillars to deliver Total Quality Solar (TQS) through comprehensive support at every stage of solar system deployment, the Green Glove program has rapidly become a vital resource for solar installers, driving faster design and deployment, higher-quality installations, inbuilt first-responder safety, and improved system performance and reliability. While nearly 70% of Green Glove engagements have come from the C&I sector, providing proactive quality assurance in larger, more complex solar installations, Tigo is now acti

Global CIO Study Reveals ROI Remains Greatest AI Adoption Barrier, Despite Three-Fold Spend Increase5.2.2025 15:00:00 CET | Press release

Lenovo-commissioned research reveals forty-two percent of global organizations plan to institutionalize Generative AI use casesThirty-seven percent of management remains skeptical toward AI Business leaders and IT decision-makers confirm AI use will reach mainstream levels of adoption as organizations devote a greater slice of their IT budgets to AI implementations, according to new IDC research commissioned by Lenovo. The new global 2025 CIO Playbook entitled It’s Time for AI-nomics, highlights AI spending expectations by IT decision-makers globally to nearly triple in 2025 compared with last year. But critical challenges include uncertain financial returns on these investments and gaps in organizational readiness. Proving ROI: The Greatest Barrier While most AI use cases have met business expectations, proving the return of these investments remains challenging—financial risk and uncertain ROI rank as the greatest barriers to AI adoption. This tension is magnified by a disconnect bet

Datassential Expands Global Menu and Limited-Time Offer Data Across Europe’s Big 5 Markets5.2.2025 14:30:00 CET | Press release

Datassential, the leading food and beverage intelligence platform connecting the dots between consumers and the industry, has announced the expansion of its cutting-edge global sales intelligence solution to include in-depth menu and limited-time offer (LTO) tracking across Europe’s Big 5 markets: France, Germany, Italy, Spain, and the U.K. This enhancement further solidifies Datassential’s position as the gold standard for empowering the foodservice ecosystem with actionable insights. With a foodservice prospecting platform tracking more than 11 million operators across 70+ countries and 100+ operator attributes, Datassential’s solution offers unparalleled tools to increase sales productivity and win rates. The addition of comprehensive menu data in these key European markets gives users access to deep insights, enabling smarter, data-driven menu recommendations tailored to operators' diverse needs. “Understanding global menus and limited-time offers has never been more critical for o

Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results5.2.2025 10:00:00 CET | Press release

The vast majority of decision makers surveyed (89%) said AI needs to have the context of how their business runs to deliver the expected results.81% of respondents said their companies plan to use AI specifically to improve business processes in the next 12 months.The majority (58%) of leaders worry that process shortcomings may limit AI’s contribution to their business. Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better. The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry

Infobip Recognized as a Worldwide CPaaS Leader by IDC MarketScape for the Third Time5.2.2025 10:00:00 CET | Press release

Global cloud communications platform Infobip has been named as a Leader in the IDC MarketScape: Worldwide Communications Platform as a Service (CPaaS) 2025 Vendor Assessment. This is the third time that Infobip has been named a Leader in this report. According to the report, “Infobip is a key player in the CPaaS market with a global footprint and strong capabilities underpinned by its broad portfolio for enterprises as well as a carrier-grade service offering.” Courtney Munroe, Research Vice President, Worldwide Telecommunications Research at IDC, said:“Infobip has an agile organization structure and appetite for innovation to meet evolving enterprise requirements that stimulates continued expansion of its capabilities and global presence. The firm’s strong breadth and depth of services has enabled it to grow rapidly while maintaining a strong financial position.” Silvio Kutić, CEO at Infobip, said: “Over the last year, Infobip has continued to invest in innovative new services. For in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye